EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

The MIF-CD74 axis drives colorectal cancer via glycolytic reprogramming and is targeted by a novel small-molecule inhibitor

Jinwei Lou, Yuhan Chen, Yue Li, Zixuan Liu, Shangshang Hu, Muzi Ding, Jian Qin, Huiling Sun, Yuqin Pan

Cellular Oncology · 22.04.2026 · 49 (3)

DOI: 10.1007/s13402-026-01202-9 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cellular Oncology, online erschienen am 22.04.2026. Verfasst von Jinwei Lou und 8 weiteren Autor:innen. Beteiligte Einrichtung: General Clinical Research Center, Nanjing First Hospital, China Pharmaceutical University, Nanjing, Jiangsu, 211122, China. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Macrophage Migration-Inhibitory Factors, Antigens, Differentiation, B-Lymphocyte, Histocompatibility Antigens Class II. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsMacrophage Migration-Inhibitory FactorsAntigens, Differentiation, B-LymphocyteHistocompatibility Antigens Class IIIntramolecular OxidoreductasesGlycolysisSmall Molecule LibrariesHumansAnimalsCell Line, TumorMetabolic ReprogrammingCell ProliferationCell MovementMice, NudeGene Expression Regulation, NeoplasticMiceSignal Transduction

Stichwörter der Autor:innen

CD74 receptorColorectal cancerF3277-0933Glycolytic reprogrammingMacrophage migration inhibitory factor (MIF)Small-molecule inhibitor

Substanzen

Macrophage Migration-Inhibitory Factorsinvariant chainAntigens, Differentiation, B-LymphocyteHistocompatibility Antigens Class IIIntramolecular OxidoreductasesMIF protein, humanSmall Molecule Libraries

Autor:innen und Institutionen

  • General Clinical Research Center, Nanjing First Hospital, China Pharmaceutical University, Nanjing, Jiangsu, 211122, China.
  • General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, 210006, China.
  • School of Medicine, Southeast University, Nanjing, Jiangsu, 210009, China.
  • General Clinical Research Center, Nanjing First Hospital, China Pharmaceutical University, Nanjing, Jiangsu, 211122, China. sunhuiling1988@yeah.net.
  • General Clinical Research Center, Nanjing First Hospital, Nanjing Medical University, Nanjing, Jiangsu, 210006, China. sunhuiling1988@yeah.net.
  • Jiangsu Collaborative Innovation Center on Cancer Personalized Medicine, Nanjing Medical University, Nanjing, Jiangsu, 211100, China. sunhuiling1988@yeah.net.

Zitieren

APA

Lou, J., Chen, Y., Li, Y., Liu, Z., Hu, S., Ding, M., Qin, J., Sun, H., & Pan, Y. (2026). The MIF-CD74 axis drives colorectal cancer via glycolytic reprogramming and is targeted by a novel small-molecule inhibitor. Cellular Oncology, 49(3). https://doi.org/10.1007/s13402-026-01202-9

Vancouver

Lou J, Chen Y, Li Y, Liu Z, Hu S, Ding M, et al. The MIF-CD74 axis drives colorectal cancer via glycolytic reprogramming and is targeted by a novel small-molecule inhibitor. Cellular Oncology. 2026;49(3). doi:10.1007/s13402-026-01202-9

BibTeX
@article{Lou2026,
  author = {Lou, Jinwei and Chen, Yuhan and Li, Yue and Liu, Zixuan and Hu, Shangshang and Ding, Muzi and Qin, Jian and Sun, Huiling and Pan, Yuqin},
  title = {The MIF-CD74 axis drives colorectal cancer via glycolytic reprogramming and is targeted by a novel small-molecule inhibitor},
  journal = {Cellular Oncology},
  year = {2026},
  volume = {49},
  number = {3},
  doi = {10.1007/s13402-026-01202-9}
}
Kostenlos starten →